Imagine the amount of stress involved in the following situation circa early March, 2020: a pandemic is upon us and you, the startup Founder is trying to close the first significant round of investment. Despite being sure the alignment between potential investor and startup is in a great shape, nothing else seems certain out there in the world as the world itself is closing its doors for an indefinite amount of time.
Despite the external odds, we’ve managed to struck an investment deal, in which Prague, Czech Republic-based Longevitytech.fund invested enough money in exchange of equity in shares to give AgeCurve Limited a real chance to prove itself.
The existence of new longevity funds willing to take risks, like that of Longevitytech.fund is hard to overvalue these days. In our case it really matched the risks AgeCurve is taking by establishing the niche market of aging and longevity focused personal proteomics.
As somebody born and raised in Budapest, Hungary, but living in the last decade in Cambridge, UK and contributing with AgeCurve to the UK economy, I’m especially happy now, that Longevitytech.fund is representing Central Europe in the slowly growing longevity investment landscape. There are options now for European longevity startups to have investors not just from UK or Germany, for instance. Democratising longevity investment is a must, too.
What made AgeCurve really go on in the last years are the actual partners and team, a handful of people I’d like to sincerely thank now and ask them to continue with us, now with much better chances.
It’s easy to say, that now, in the time of an unprecedented public health crisis, companies focusing on healthy longevity and being able to connect it to individual health information have a good chance to grow and flourish. It’s easy to say but not easy to do. The AgeCurve end user experience starts with ‘aging scores’, not with ‘health scares’; we try to provide tools to potentially help improve the scores, not to aggravate the scares. AgeCurve is a young startup with low aging scores, and thanks to Longevitytech.fund we have been able to significantly improve our financial health.